FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Gianantonio Rosti

Research Profile

Disorders

Chemicals & Drugs

Procedures

Concepts & Ideas

Co-author Network

Publications

TOP 3
Andreas Hochhaus; Albert Hoenekopp; Carmino De Souza; Gabriel Etienne; Xiaolin Fan; Matt E Kalaycio; Hagop M Kantarjian; Dong-Wook Kim; Mineo Kurokawa; Richard A Larson; Gianantonio Rosti; Giuseppe Saglio; Yaping Shou; Timothy P Hughes
Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase.
Mario Arpinati; Marilina Amabile; Giuseppe Bandini; Maria Teresa Bochicchio; Francesca Bonifazi; Fausto Castagnetti; Giovanni Martinelli; Gianantonio Rosti; Marta Stanzani; Giulia Tolomelli; Michele Baccarani
Molecular Monitoring of BCR-ABL Transcripts after Allogeneic Stem Cell Transplantation for Chronic Myeloid Leukemia.
Antonella Russo Rossi; Fabio Stagno; Mario Tiribelli; Giuseppe Visani; Elisabetta Abruzzese; Francesco Albano; Giuliana Alimena; Mario Annunziata; Massimo Breccia; Fausto Castagnetti; francesco cavazzini; Carmen Fava; Antonella Gozzini; Luigiana Luciano; Bruno Martino; Pellegrino Musto; Patrizia Pregno; Gianantonio Rosti; Nicola Sgherza; Giorgina Specchia
Outcome of 82 chronic myeloid leukemia patients treated with nilotinib or dasatinib after failure of two prior tyrosine kinase inhibitors.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Gianantonio Rosti (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Andreas Hochhaus; Albert Hoenekopp; Carmino De Souza; Gabriel Etienne; Xiaolin Fan; Matt E Kalaycio; Hagop M Kantarjian; Dong-Wook Kim; Mineo Kurokawa; Richard A Larson; Gianantonio Rosti; Giuseppe Saglio; Yaping Shou; Timothy P Hughes
Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase.
Blood 2013;121(18):3703-8.
2013: Mario Arpinati; Marilina Amabile; Giuseppe Bandini; Maria Teresa Bochicchio; Francesca Bonifazi; Fausto Castagnetti; Giovanni Martinelli; Gianantonio Rosti; Marta Stanzani; Giulia Tolomelli; Michele Baccarani
Molecular Monitoring of BCR-ABL Transcripts after Allogeneic Stem Cell Transplantation for Chronic Myeloid Leukemia.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2013;19(5):735-40.
2013: Antonella Russo Rossi; Fabio Stagno; Mario Tiribelli; Giuseppe Visani; Elisabetta Abruzzese; Francesco Albano; Giuliana Alimena; Mario Annunziata; Massimo Breccia; Fausto Castagnetti; francesco cavazzini; Carmen Fava; Antonella Gozzini; Luigiana Luciano; Bruno Martino; Pellegrino Musto; Patrizia Pregno; Gianantonio Rosti; Nicola Sgherza; Giorgina Specchia
Outcome of 82 chronic myeloid leukemia patients treated with nilotinib or dasatinib after failure of two prior tyrosine kinase inhibitors.
Haematologica 2013;98(3):399-403.
2013: Mario Tiribelli; Elisabetta Abruzzese; Francesco Albano; Giuliana Alimena; Mario Annunziata; Massimo Breccia; Giovanna Rege Cambrin; Fausto Castagnetti; Renato Fanin; Carmen Fava; Antonella Gozzini; Roberto Latagliata; Luigiana Luciano; Enrico Montefusco; Pellegrino Musto; Fabrizio Pane; Patrizia Pregno; Gianantonio Rosti; Fabio Stagno; Paolo Vigneri
Impact of BCR-ABL mutations on response to dasatinib after imatinib failure in elderly patients with chronic-phase chronic myeloid leukemia.
Annals of hematology 2013;92(2):179-83.
2012: Marzia Defina; Alessandro Gozzetti; Antonella Gozzini; Micaela Ippoliti; Francesco Lauria; Gianantonio Rosti; Marzia Salvucci; Mario Tiribelli; Elisabetta Abruzzese; Lara Aprile; Claudia Baratè; Massimo Breccia; Fausto Castagnetti; Rosaria Crupi; Monica Bocchia
Evaluation of residual CD34(+) Ph(+) progenitor cells in chronic myeloid leukemia patients who have complete cytogenetic response during first-line nilotinib therapy.
Cancer 2012;118(21):5265-9.
2012: Fabio Efficace; F Gherlinzoni; A Iurlo; Giuliana Alimena; M Baccarani; Massimo Breccia; Fausto Castagnetti; F Cottone; S Pardini; A R Rossi; Gianantonio Rosti; M Salvucci; Mario Tiribelli; M Vignetti; F Mandelli
Investigating factors associated with adherence behaviour in patients with chronic myeloid leukemia: an observational patient-centered outcome study.
British journal of cancer 2012;107(6):904-9.
2012: Francis Giles; Bjorn Gjertsen; Boris Labar; François-Xavier Mahon; Ronan T Swords; Anna Turkina; Gianantonio Rosti
Developmental Therapeutics Consortium report on study design effects on trial outcomes in chronic myeloid leukaemia.
European journal of clinical investigation 2012;42(9):1016-26.
2012: Simona Soverini; Ilaria Iacobucci; Giovanni Martinelli; Gianantonio Rosti; Michele Baccarani
Advances in treatment of chronic myeloid leukemia with tyrosine kinase inhibitors: the evolving role of Bcr-Abl mutations and mutational analysis.
Pharmacogenomics 2012;13(11):1271-84.
2012: Simona Luatti; Marco Mancini; Giovanni Martinelli; Giulia Marzocchi; Francesca Palandri; Giandomenico Palka; Fabrizio Pane; Giovanna Rege-Cambrin; Gianantonio Rosti; Giuseppe Saglio; Giorgina Specchia; Nicoletta Testoni; Alfonso Zaccaria; Lucia Zanatta; Elisabetta Abruzzese; Gaia Ameli; Michele Baccarani; Carmen Baldazzi; Paolo Bernasconi; Maria Adele Capucci; Fausto Castagnetti; Alessandro Gozzetti; Maria Grazia Grimoldi; Gabriele Gugliotta; Ilaria Iacobucci
Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis.
Blood 2012;120(4):761-7.
2012: Joëlle Guilhot; Michele Baccarani; Francisco Cervantes; Richard E Clark; François Guilhot; Andreas Hochhaus; Sergei Kulikov; Jiri Mayer; Andreas L Petzer; Gianantonio Rosti; Philippe Rousselot; Giuseppe Saglio; Susanne Saussele; Bengt Simonsson; Juan-Luis Steegmann; Andrey Zaritskey; Rüdiger Hehlmann
Definitions, methodological and statistical issues for phase 3 clinical trials in chronic myeloid leukemia: a proposal by the European LeukemiaNet.
Blood 2012;119(25):5963-71.
2012: Gianantonio Rosti; Fausto Castagnetti; Gabriele Gugliotta; Francesca Palandri; Michele Baccarani
Physician's guide to the clinical management of adverse events on nilotinib therapy for the treatment of CML.
Cancer treatment reviews 2012;38(3):241-8.
2012: Gianantonio Rosti; Fausto Castagnetti; Gabriele Gugliotta; Francesca Palandri; Michele Baccarani
Second-generation BCR-ABL inhibitors for frontline treatment of chronic myeloid leukemia in chronic phase.
Critical reviews in oncology/hematology 2012;82(2):159-70.
2012: Verena Hoffmann; Doris Lindoerfer; Gert Ossenkoppele; Markus Pfirrmann; Kimmo Porkka; Gianantonio Rosti; Susanne Saussele; Bengt Simonsson; Michele Baccarani; François Guilhot; Joelle Guilhot; Joerg Hasford; Rüdiger Hehlmann
The EUTOS CML score aims to support clinical decision-making.
Blood 2012;119(12):2966-7.
2012: Pier Paolo Piccaluga; Clara Bertuzzi; Antonio De Leo; Stefania Paolini; Gianantonio Rosti
First-line treatment of chronic myeloid leukemia with nilotinib: critical evaluation.
Journal of blood medicine 2012;3():151-6.
2011: Gabriele Gugliotta; Francesca Palandri; Michele Baccarani; Fausto Castagnetti; Gianantonio Rosti
Imatinib in chronic myeloid leukemia elderly patients.
Aging 2011;3(12):1125-6.
2011: Simona Soverini; Nicoletta Testoni; Giulia Marzocchi; Francesca Palandri; Gianantonio Rosti; Michele Baccarani; Fausto Castagnetti; Caterina De Benedittis; Alessandra Gnani; Gabriele Gugliotta; Ilaria Iacobucci; Simona Luatti; Giovanni Martinelli
Low-level Bcr-Abl mutations are very rare in chronic myeloid leukemia patients who are in major molecular response on first-line nilotinib.
Leukemia research 2011;35(11):1527-9.
2011: Fabio Efficace; Giuseppe Fioritoni; Pietro Leoni; Luciano Levato; Luigia Luciano; Franco Mandelli; Bruno Martino; Alessandro Rambaldi; Antonella Russo Rossi; Gianantonio Rosti; Simona Sica; Maria Pina Simula; Diamante Turri; Stefano Ulisciani; Dino Veneri; Marco Vignetti; Giuliana Alimena; Michele Baccarani; Claudia Baratè; Micaela Bergamaschi; Massimo Breccia; Francesco Cottone; Melissa Dabusti; Giorgio Lambertenghi Deliliers; Francesco Di Raimondo
Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population.
Blood 2011;118(17):4554-60.
2011: Massimo Breccia; Fausto Castagnetti; francesco cavazzini; Carmen Fava; Antonella Gozzini; Roberto Latagliata; Luigiana Luciano; Fabrizio Pane; Patrizia Pregno; Giovanna Rege-Cambrin; Gianantonio Rosti; Antonella Russo Rossi; Valeria Santini; Simona Sica; Giorgina Specchia; Fabio Stagno; Paolo Vigneri; Elisabetta Abruzzese; Mario Annunziata; Giuliana Alimena
Charlson comorbidity index and adult comorbidity evaluation-27 scores might predict treatment compliance and development of pleural effusions in elderly patients with chronic myeloid leukemia treated with second-line dasatinib.
Haematologica 2011;96(10):1457-61.
2011: Hagop M Kantarjian; Richard A Larson; Hirohisa Nakamae; Gianantonio Rosti; Giuseppe Saglio; Leif Stenke; Carmino De Souza; Rick E Blakesley; Ian W Flinn; Neil J Gallagher; Yeow Tee Goh; Andreas Hochhaus; Albert Hoenekopp; Timothy P Hughes
Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial.
The lancet oncology 2011;12(9):841-51.
2011: Simona Soverini; Michele Baccarani; Nicholas C P Cross; Thomas Ernst; Franz Gruber; Andreas Hochhaus; Thoralf Lange; Martin C Müller; Franck E Nicolini; Fabrizio Pane; Kimmo Porkka; Gianantonio Rosti; Giuseppe Saglio; Giovanni Martinelli
BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet.
Blood 2011;118(5):1208-15.
2011: Joerg Hasford; Michele Baccarani; François Guilhot; Joelle Guilhot; Verena Hoffmann; Doris Lindoerfer; Gert Ossenkoppele; Markus Pfirrmann; Kimmo Porkka; Gianantonio Rosti; Susanne Saussele; Bengt Simonsson; Rudiger Hehlmann
Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score.
Blood 2011;118(3):686-92.
2011: Anthony Oyekunle; Michele Baccarani; Fausto Castagnetti; Gabriele Gugliotta; Simona Soverini; Gianantonio Rosti
F317L BCR-ABL1 kinase domain mutation associated with a sustained major molecular response in a CML patient on dasatinib.
Leukemia research 2011;35(7):e118-20.
2011: Giulia Marzocchi; Anna Montaldi; Francesca Palandri; Fabrizio Pane; Gianantonio Rosti; Giuseppe Saglio; Alessandra Santoro; Mario Sessarego; Giorgina Specchia; Monica Stacchini; Nicoletta Testoni; Laura Valori; Marilina Amabile; Michele Baccarani; Carmen Baldazzi; Laura Bonaldi; Fausto Castagnetti; Anna Maria Cianciulli; Giancarlo Discepoli; Francesca Giacobbi; Giovanni Giudici; Ursula Giussani; Gabriele Gugliotta; Simona Luatti; Giovanni Martinelli
Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysis.
Blood 2011;117(25):6793-800.
2011: Jorge E Cortes; Andreas Hochhaus; Philipp D le Coutre; Gianantonio Rosti; Javier Pinilla-Ibarz; Elias Jabbour; Kathryn Gillis; Richard C Woodman; Rick E Blakesley; Francis J Giles; Hagop M Kantarjian; Michele Baccarani
Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinib.
Blood 2011;117(21):5600-6.
2011: Tom Lenaerts; Fausto Castagnetti; Arne Traulsen; Jorge M Pacheco; Gianantonio Rosti; David Dingli
Explaining the in vitro and in vivo differences in leukemia therapy.
Cell cycle (Georgetown, Tex.) 2011;10(10):1540-4.
2011: Simona Soverini; Gianantonio Rosti; Michele Baccarani; Ilaria Iacobucci; Giovanni Martinelli
Choosing the best second-line tyrosine kinase inhibitor in imatinib-resistant chronic myeloid leukemia patients harboring Bcr-Abl kinase domain mutations: how reliable is the IC₅₀?
The oncologist 2011;16(6):868-76.
2011: Simona Soverini; J Score; Ilaria Iacobucci; Angela Poerio; A Lonetti; A Gnani; S Colarossi; A Ferrari; F Castagnetti; Gianantonio Rosti; F Cervantes; A Hochhaus; M Delledonne; A Ferrarini; M Sazzini; Donata Luiselli; Michele Baccarani; N C P Cross; giovanni martinelli
IDH2 somatic mutations in chronic myeloid leukemia patients in blast crisis.
Leukemia 2011;25(1):178-81.
2010: Francis J Giles; Gianantonio Rosti; Photis Beris; Richard E Clark; Philipp le Coutre; Francois-Xavier Mahon; Juan-Luis Steegmann; Peter Valent; Giuseppe Saglio
Nilotinib is superior to imatinib as first-line therapy of chronic myeloid leukemia: the ENESTnd study.
Expert review of hematology 2010;3(6):665-73.
2010: Francesca Palandri; Fausto Castagnetti; Ilaria Iacobucci; Giovanni Martinelli; Marilina Amabile; Gabriele Gugliotta; Angela Poerio; Nicoletta Testoni; Massimo Breccia; Monica Bocchia; Monica Crugnola; Giovanna Rege-Cambrin; Bruno Martino; Ivana Pierri; Franca Radaelli; Giorgina Specchia; Fabrizio Pane; Giuseppe Saglio; Gianantonio Rosti; Michele Baccarani
The response to imatinib and interferon-alpha is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase.
Haematologica 2010;95(8):1415-9.
2010: Alfonso Zaccaria; Nicoletta Testoni; Anna Maria Valenti; Simona Luatti; Michela Tonelli; Giulia Marzocchi; Raffaella Cipriani; Carmen Baldazzi; Barbara Giannini; Monica Stacchini; Carla Gamberini; Fausto Castagnetti; Gianantonio Rosti; Annalisa Azzena; Francesco Cavazzini; Anna Maria Cianciulli; Alessia Dalsass; Emilio Donti; Emilia Giugliano; Alessandro Gozzetti; Maria Grazia Grimoldi; Sonia Ronconi; Alessandra Santoro; Francesco Spedicato; Lucia Zanatta; Michele Baccarani
Chromosome abnormalities additional to the Philadelphia chromosome at the diagnosis of chronic myelogenous leukemia: pathogenetic and prognostic implications.
Cancer genetics and cytogenetics 2010;199(2):76-80.
2010: Fausto Castagnetti; Nicoletta Testoni; Simona Luatti; Giulia Marzocchi; Marco Mancini; Simonetta Kerim; Emilia Giugliano; Francesco Albano; Antonio Cuneo; Elisabetta Abruzzese; Bruno Martino; Francesca Palandri; Marilina Amabile; Ilaria Iacobucci; Giuliana Alimena; Fabrizio Pane; Giovanni Martinelli; Giuseppe Saglio; Michele Baccarani; Gianantonio Rosti
Deletions of the derivative chromosome 9 do not influence the response and the outcome of chronic myeloid leukemia in early chronic phase treated with imatinib mesylate: GIMEMA CML Working Party analysis.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(16):2748-54.
2010: Gianantonio Rosti; Fausto Castagnetti; Gabriele Gugliotta; Francesca Palandri; Giovanni Martinelli; Michele Baccarani
Dasatinib and nilotinib in imatinib-resistant Philadelphia-positive chronic myelogenous leukemia: a 'head-to-head comparison'.
Leukemia & lymphoma 2010;51(4):583-91.
2010: Massimo Breccia; Francesca Palandri; Anna Paola Iori; Elisabetta Colaci; Roberto Latagliata; Fausto Castagnetti; Giovanni Fernando Torelli; Sara Usai; Veronica Valle; Giovanni Martinelli; Gianantonio Rosti; Robin Foà; Michele Baccarani; Giuliana Alimena
Second-generation tyrosine kinase inhibitors before allogeneic stem cell transplantation in patients with chronic myeloid leukemia resistant to imatinib.
Leukemia research 2010;34(2):143-7.
2010: Kimbach Tran Carpiuc; Gianantonio Rosti; Fausto Castagnetti; Maarten Treur; Jennifer Stephens
Indirect comparisons of second-generation tyrosine kinase inhibitors in CML: case study using baseline population characteristics.
OncoTargets and therapy 2010;3():205-10.
2009: Gianantonio Rosti; Francesca Palandri; Fausto Castagnetti; Massimo Breccia; Luciano Levato; Gabriele Gugliotta; Adele Capucci; Michele Cedrone; Carmen Fava; Tamara Intermesoli; Giovanna Rege Cambrin; Fabio Stagno; Mario Tiribelli; Marilina Amabile; Simona Luatti; Angela Poerio; Simona Soverini; Nicoletta Testoni; Giovanni Martinelli; Giuliana Alimena; Fabrizio Pane; Giuseppe Saglio; Michele Baccarani
Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia.
Blood 2009;114(24):4933-8.
2009: Nicoletta Testoni; Giulia Marzocchi; Simona Luatti; Marilina Amabile; Carmen Baldazzi; Monica Stacchini; Mauro Nanni; Giovanna Rege-Cambrin; Emilia Giugliano; Ursula Giussani; Elisabetta Abruzzese; Simonetta Kerim; Maria Grazia Grimoldi; Alessandro Gozzetti; Barbara Crescenzi; Carlo Carcassi; Paolo Bernasconi; Antonio Cuneo; Francesco Albano; Giuseppina Fugazza; Alfonso Zaccaria; Giovanni Martinelli; Fabrizio Pane; Gianantonio Rosti; Michele Baccarani
Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response: a study of the GIMEMA CML WP.
Blood 2009;114(24):4939-43.
2009: Francesca Palandri; Fausto Castagnetti; Simona Soverini; Angela Poerio; Gabriele Gugliotta; Simona Luatti; Marilina Amabile; Giovanni Martinelli; Gianantonio Rosti; Michele Baccarani
Pancreatic enzyme elevation in chronic myeloid leukemia patients treated with nilotinib after imatinib failure.
Haematologica 2009;94(12):1758-61.
2009: Carmen Baldazzi; Simona Luatti; Giulia Marzocchi; Monica Stacchini; Carla Gamberini; Fausto Castagnetti; Francesca Palandri; Gianantonio Rosti; Michele Baccarani; Nicoletta Testoni
Emergence of clonal chromosomal abnormalities in Philadelphia negative hematopoiesis in chronic myeloid leukemia patients treated with nilotinib after failure of imatinib therapy.
Leukemia research 2009;33(12):e218-20.
2009: Simona Soverini; Alessandra Gnani; Sabrina Colarossi; Fausto Castagnetti; Elisabetta Abruzzese; Stefania Paolini; Serena Merante; Ester Orlandi; Silvia de Matteis; Antonella Gozzini; Ilaria Iacobucci; Francesca Palandri; Gabriele Gugliotta; Cristina Papayannidis; Angela Poerio; Marilina Amabile; Daniela Cilloni; Gianantonio Rosti; Michele Baccarani; Giovanni Martinelli
Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors.
Blood 2009;114(10):2168-71.
2009: Jane F Apperley; Jorge E Cortes; Dong-Wook Kim; Lydia Roy; Gail J Roboz; Gianantonio Rosti; Eduardo O Bullorsky; Elisabetta Abruzzese; Andreas Hochhaus; Dominik Heim; Carmino A de Souza; Richard A Larson; Jeffrey H Lipton; H Jean Khoury; Hyeoung-Joon Kim; Christian Sillaber; Timothy P Hughes; Philipp Erben; Jan M. Van Tornout; Richard M Stone
Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(21):3472-9.
2009: Michele Baccarani; Gianantonio Rosti; Fausto Castagnetti; Ibrahim Haznedaroglu; Kimmo Porkka; Elisabetta Abruzzese; Giuliana Alimena; Hans Ehrencrona; Henrik Hjorth-Hansen; Veli Kairisto; Luciano Levato; giovanni martinelli; Arnon Nagler; Johan Lanng Nielsen; Ugur Ozbek; Francesca Palandri; Fausto Palmieri; Fabrizio Pane; Giovanna Rege-Cambrin; Domenico Russo; Giorgina Specchia; Nicoletta Testoni; Ole Weiss-Bjerrum; Giuseppe Saglio; Bengt Simonsson
Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study.
Blood 2009;113(19):4497-504.
2009: Fausto Castagnetti; Francesca Palandri; Marilina Amabile; Nicoletta Testoni; Simona Luatti; Simona Soverini; Ilaria Iacobucci; Massimo Breccia; Giovanna Rege-Cambrin; Fabio Stagno; Giorgina Specchia; Piero Galieni; Franco Iuliano; Fabrizio Pane; Giuseppe Saglio; Giuliana Alimena; giovanni martinelli; Michele Baccarani; Gianantonio Rosti
Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party.
Blood 2009;113(15):3428-34.
2009: Francesca Palandri; Ilaria Iacobucci; Simona Soverini; Fausto Castagnetti; Angela Poerio; Nicoletta Testoni; Giuliana Alimena; Massimo Breccia; Giovanna Rege-Cambrin; Mario Tiribelli; Riccardo Varaldo; Elisabetta Abruzzese; Bruno Martino; Luigiana Luciano; Fabrizio Pane; Giuseppe Saglio; giovanni martinelli; Michele Baccarani; Gianantonio Rosti
Treatment of Philadelphia-positive chronic myeloid leukemia with imatinib: importance of a stable molecular response.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(3):1059-63.
2009: Francesca Palandri; Fausto Castagnetti; Giuliana Alimena; Nicoletta Testoni; Massimo Breccia; Simona Luatti; Giovanna Rege-Cambrin; Fabio Stagno; Giorgina Specchia; Bruno Martino; Luciano Levato; Serena Merante; Anna Maria Liberati; Fabrizio Pane; Giuseppe Saglio; Daniele Alberti; giovanni martinelli; Michele Baccarani; Gianantonio Rosti
The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML Working Party experience after a 7-year follow-up.
Haematologica 2009;94(2):205-12.
2009: Francesca Palandri; Nicoletta Testoni; Simona Luatti; Giulia Marzocchi; Carmen Baldazzi; Monica Stacchini; Fausto Castagnetti; Massimo Breccia; Giorgina Specchia; Fabrizio Pane; Giuseppe Saglio; giovanni martinelli; Michele Baccarani; Gianantonio Rosti
Influence of additional cytogenetic abnormalities on the response and survival in late chronic phase chronic myeloid leukemia patients treated with imatinib: long-term results.
Leukemia & lymphoma 2009;50(1):114-8.
2008: Francesca Palandri; Fausto Castagnetti; Nicoletta Testoni; Simona Luatti; Giulia Marzocchi; Simona Bassi; Massimo Breccia; Giuliana Alimena; Ester Pungolino; Giovanna Rege-Cambrin; Riccardo Varaldo; Maurizio Miglino; Giorgina Specchia; Elisa Zuffa; Felicetto Ferrara; Monica Bocchia; Giuseppe Saglio; Fabrizio Pane; Daniele Alberti; giovanni martinelli; Michele Baccarani; Gianantonio Rosti
Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up.
Haematologica 2008;93(12):1792-6.
2008: Simonetta Pardini; Claudio Fozza; Salvatore Contini; Elena Rimini; Emanuela Ottaviani; Marilina Amabile; Gianantonio Rosti; Maurizio Longinotti
A case of coexistence between JAK2V617F and BCR /ABL.
European journal of haematology 2008;81(1):75-6.
2008: Seonaid M Pye; Jorge Cortes; Patricia Ault; Alan Hatfield; Andrew Lamb; Richard Pilot; Gianantonio Rosti; Jane F Apperley
The effects of imatinib on pregnancy outcome.
Blood 2008;111(12):5505-8.
2008: Francesca Palandri; Ilaria Iacobucci; Fausto Castagnetti; Nicoletta Testoni; Angela Poerio; Marilina Amabile; Massimo Breccia; Tamara Intermesoli; Francesco Iuliano; Giovanna Rege-Cambrin; Mario Tiribelli; Maurizio Miglino; Fabrizio Pane; Giuseppe Saglio; giovanni martinelli; Gianantonio Rosti; Michele Baccarani
Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon-alpha: 5-year outcome.
Haematologica 2008;93(5):770-4.
2008: Francesca Palandri; Ilaria Iacobucci; giovanni martinelli; Marilina Amabile; Angela Poerio; Nicoletta Testoni; Simona Soverini; Fausto Castagnetti; Antonio de Vivo; Massimo Breccia; Giorgina Specchia; Elisabetta Abruzzese; Bruno Martino; Daniela Cilloni; Giuseppe Saglio; Fabrizio Pane; Anna Marina Liberati; Gianantonio Rosti; Michele Baccarani
Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, philadelphia-positive chronic myeloid leukemia: the GIMEMA Working Party on CML.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(1):106-11.
2007: Pier Paolo Piccaluga; Michela Rondoni; Stefania Paolini; Gianantonio Rosti; giovanni martinelli; Michele Baccarani
Imatinib mesylate in the treatment of hematologic malignancies.
Expert opinion on biological therapy 2007;7(10):1597-611.
2007: Michele Baccarani; Daniela Cilloni; Michela Rondoni; Emanuela Ottaviani; Francesca Messa; Serena Merante; Mario Tiribelli; Francesco Buccisano; Nicoletta Testoni; Enrico Gottardi; Antonio de Vivo; Emilia Giugliano; Ilaria Iacobucci; Stefania Paolini; Simona Soverini; Gianantonio Rosti; Francesca Rancati; Cinzia Astolfi; Fabrizio Pane; Giuseppe Saglio; giovanni martinelli
The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study.
Haematologica 2007;92(9):1173-9.
2007: Giovanni Martinelli; Ilaria Iacobucci; Simona Soverini; Francesca Palandri; Fausto Castagnetti; Gianantonio Rosti; Michele Baccarani
Nilotinib: a novel encouraging therapeutic option for chronic myeloid leukemia patients with imatinib resistance or intolerance.
Biologics : targets & therapy 2007;1(2):121-7.
2007: Simona Soverini; Sabrina Colarossi; Alessandra Gnani; Fausto Castagnetti; Gianantonio Rosti; Costanza Bosi; Stefania Paolini; Michela Rondoni; Pier Paolo Piccaluga; Francesca Palandri; Panagiota Giannoulia; Giulia Marzocchi; Simona Luatti; Nicoletta Testoni; Ilaria Iacobucci; Daniela Cilloni; Giuseppe Saglio; Michele Baccarani; giovanni martinelli
Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain.
Haematologica 2007;92(3):401-4.
2007: Simona Soverini; giovanni martinelli; Sabrina Colarossi; Alessandra Gnani; Michela Rondoni; Fausto Castagnetti; Stefania Paolini; Gianantonio Rosti; Michele Baccarani
Second-line treatment with dasatinib in patients resistant to imatinib can select novel inhibitor-specific BCR-ABL mutants in Ph+ ALL.
The lancet oncology 2007;8(3):273-4.
2007: Francesca Palandri; Marilina Amabile; Gianantonio Rosti; Giuseppe Bandini; F Benedetti; E Usala; E Angelucci; Mario Tiribelli; R Fanin; giovanni martinelli; Michele Baccarani
Imatinib therapy for chronic myeloid leukemia patients who relapse after allogeneic stem cell transplantation: a molecular analysis.
Bone marrow transplantation 2007;39(3):189-91.
2007: Gianantonio Rosti; Ilaria Iacobucci; Simona Bassi; Fausto Castagnetti; Marilina Amabile; Daniela Cilloni; Angela Poerio; Simona Soverini; Francesca Palandri; Giovanna Rege-Cambrin; Franco Iuliano; Giuliana Alimena; Roberto Latagliata; Nicoletta Testoni; Fabrizio Pane; Giuseppe Saglio; Michele Baccarani; giovanni martinelli
Impact of age on the outcome of patients with chronic myeloid leukemia in late chronic phase: results of a phase II study of the GIMEMA CML Working Party.
Haematologica 2007;92(1):101-5.
2007: Gianantonio Rosti; giovanni martinelli; Michele Baccarani
In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'.
Nature medicine 2007;13(1):15; author reply 15-6.
2006: Simona Soverini; Sabrina Colarossi; Alessandra Gnani; Gianantonio Rosti; Fausto Castagnetti; Angela Poerio; Ilaria Iacobucci; Marilina Amabile; Elisabetta Abruzzese; Ester Orlandi; Franca Radaelli; Fabrizio Ciccone; Mario Tiribelli; Roberto di Lorenzo; Clementina Caracciolo; Barbara Izzo; Fabrizio Pane; Giuseppe Saglio; Michele Baccarani; giovanni martinelli
Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(24):7374-9.
2006: Simona Soverini; giovanni martinelli; Sabrina Colarossi; Alessandra Gnani; Fausto Castagnetti; Gianantonio Rosti; Costanza Bosi; Stefania Paolini; Michela Rondoni; Pier Paolo Piccaluga; Francesca Palandri; Panagiota Giannoulia; Giulia Marzocchi; Simona Luatti; Nicoletta Testoni; Ilaria Iacobucci; Daniela Cilloni; Giuseppe Saglio; Michele Baccarani
Presence or the emergence of a F317L BCR-ABL mutation may be associated with resistance to dasatinib in Philadelphia chromosome-positive leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(33):e51-2.
2006: Ilaria Iacobucci; Giuseppe Saglio; Gianantonio Rosti; Nicoletta Testoni; Fabrizio Pane; Marilina Amabile; Angela Poerio; Simona Soverini; Simona Bassi; Daniela Cilloni; Renato Bassan; Massimo Breccia; Francesco Lauria; Barbara Izzo; Serena Merante; Francesco Frassoni; Stefania Paolini; Enrico Montefusco; Michele Baccarani; giovanni martinelli
Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(10):3037-42.
2006: giovanni martinelli; Ilaria Iacobucci; Gianantonio Rosti; Fabrizio Pane; Marilina Amabile; Fausto Castagnetti; Daniela Cilloni; Simona Soverini; Nicoletta Testoni; Giorgina Specchia; Serena Merante; Alfonso Zaccaria; F Frassoni; Giuseppe Saglio; Michele Baccarani
Prediction of response to imatinib by prospective quantitation of BCR-ABL transcript in late chronic phase chronic myeloid leukemia patients.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2006;17(3):495-502.
2006: Ilaria Iacobucci; Gianantonio Rosti; Marilina Amabile; Angela Poerio; Simona Soverini; Daniela Cilloni; Nicoletta Testoni; Elisabetta Abruzzese; Enrico Montefusco; Emanuela Ottaviani; Franco Iuliano; Domenico Russo; marco gobbi; Giuliana Alimena; Bruno Martino; Carolina Terragna; Fabrizio Pane; Giuseppe Saglio; Michele Baccarani; giovanni martinelli
Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(3):454-9.
2005: giovanni martinelli; Simona Soverini; Gianantonio Rosti; Michele Baccarani
Dual tyrosine kinase inhibitors in chronic myeloid leukemia.
Leukemia 2005;19(11):1872-9.
2005: Gianantonio Rosti; Michele Baccarani
Does early stem-cell transplantation have a role in chronic myeloid leukaemia? Against the proposal.
The lancet oncology 2005;6(9):722-3.
2005: Simona Soverini; giovanni martinelli; Gianantonio Rosti; Simona Bassi; Marilina Amabile; Angela Poerio; Barbara Giannini; Elena Trabacchi; Fausto Castagnetti; Nicoletta Testoni; Simona Luatti; Antonio de Vivo; Daniela Cilloni; Barbara Izzo; Milena Fava; Elisabetta Abruzzese; Daniele Alberti; Fabrizio Pane; Giuseppe Saglio; Michele Baccarani
ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(18):4100-9.
2005: Francesca Bonifazi; Giuseppe Bandini; Marta Stanzani; Francesca Palandri; Barbara Giannini; Mario Arpinati; Gianantonio Rosti; Michele Baccarani
In vivo T-cell depletion with low-dose ATG is effective in reducing cGVHD after peripheral blood stem cell myeloablative sibling transplants in CML: results from a prospective phase II study.
Bone marrow transplantation 2005;35(10):1025-6.
2005: giovanni martinelli; Simona Soverini; Gianantonio Rosti; Daniela Cilloni; Michele Baccarani
New tyrosine kinase inhibitors in chronic myeloid leukemia.
Haematologica 2005;90(4):534-41.
2004: Michele Baccarani; giovanni martinelli; Gianantonio Rosti; Elena Trabacchi; Nicoletta Testoni; Simona Bassi; Marilina Amabile; Simona Soverini; Fausto Castagnetti; Daniela Cilloni; Barbara Izzo; Antonio de Vivo; Emanuela Messa; Francesca Bonifazi; Angela Poerio; Simona Luatti; Emilia Giugliano; Daniele Alberti; Gianluca Fincato; Domenico Russo; Fabrizio Pane; Giuseppe Saglio
Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemia.
Blood 2004;104(13):4245-51.
2004: Simona Soverini; giovanni martinelli; Marilina Amabile; Angela Poerio; Michele Bianchini; Gianantonio Rosti; Fabrizio Pane; Giuseppe Saglio; Michele Baccarani
Denaturing-HPLC-based assay for detection of ABL mutations in chronic myeloid leukemia patients resistant to Imatinib.
Clinical chemistry 2004;50(7):1205-13.
2004: Gianantonio Rosti; giovanni martinelli; Simona Bassi; Marilina Amabile; Elena Trabacchi; Barbara Giannini; Daniela Cilloni; Barbara Izzo; Antonio de Vivo; Nicoletta Testoni; Giovanna Rege Cambrin; Francesca Bonifazi; Simona Soverini; Simona Luatti; Enrico Gottardi; Daniele Alberti; Fabrizio Pane; Francesco Salvatore; Giuseppe Saglio; Michele Baccarani
Molecular response to imatinib in late chronic-phase chronic myeloid leukemia.
Blood 2004;103(6):2284-90.
2004: giovanni martinelli; Michele Malagola; Emanuela Ottaviani; Gianantonio Rosti; Elena Trabacchi; Michele Baccarani
Imatinib mesylate can induce complete molecular remission in FIP1L1-PDGFR-a positive idiopathic hypereosinophilic syndrome.
Haematologica 2004;89(2):236-7.
2003: Gianantonio Rosti; Nicoletta Testoni; giovanni martinelli; Michele Baccarani
The cytogenetic response as a surrogate marker of survival.
Seminars in hematology 2003;40(2 Suppl 2):56-61.
2003: Gianantonio Rosti; Elena Trabacchi; Simona Bassi; Francesca Bonifazi; Antonio de Vivo; giovanni martinelli; Daniele Alberti; Gianluca Fincato; Giuseppe Saglio; Michele Baccarani
Risk and early cytogenetic response to imatinib and interferon in chronic myeloid leukemia.
Haematologica 2003;88(3):256-9.
2003: Gianantonio Rosti; Francesca Bonifazi; Elena Trabacchi; Antonio de Vivo; Simona Bassi; giovanni martinelli; Nicoletta Testoni; Domenico Russo; Michele Baccarani
A phase II study of alpha-interferon and oral arabinosyl cytosine (YNK01) in chronic myeloid leukemia.
Leukemia 2003;17(3):554-9.
2003: Michele Baccarani; Domenico Russo; Gianantonio Rosti; giovanni martinelli
Interferon-alfa for chronic myeloid leukemia.
Seminars in hematology 2003;40(1):22-33.
2002: giovanni martinelli; Marilina Amabile; Barbara Giannini; Carolina Terragna; Emanuela Ottaviani; Simona Soverini; Giuseppe Saglio; Gianantonio Rosti; Michele Baccarani
Novel types of bcr-abl transcript with breakpoints in BCR exon 8 found in Philadelphia positive patients with typical chronic myeloid leukemia retain the sequence encoding for the DBL- and CDC24 homology domains but not the pleckstrin homology one.
Haematologica 2002;87(7):688-94; discussion 694.
2002: Michele Baccarani; Gianantonio Rosti; Antonio de Vivo; Francesca Bonifazi; Domenico Russo; giovanni martinelli; Nicoletta Testoni; Marilina Amabile; Mauro Fiacchini; Enrico Montefusco; Giuseppe Saglio; Sante Tura
A randomized study of interferon-alpha versus interferon-alpha and low-dose arabinosyl cytosine in chronic myeloid leukemia.
Blood 2002;99(5):1527-35.
2001: Francesca Bonifazi; Antonio de Vivo; Gianantonio Rosti; françois guilhot; Joëlle Guilhot; Elena Trabacchi; Rüdiger Hehlmann; A Hochhaus; P C Shepherd; Juan Luis Steegmann; Hanneke C Kluin-Nelemans; J Thaler; B Simonsson; A Louwagie; J Reiffers; François-Xavier Mahon; Enrico Montefusco; Giuliana Alimena; Joerg Hasford; S Richards; Giuseppe Saglio; Nicoletta Testoni; giovanni martinelli; Sante Tura; Michele Baccarani
Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders.
Blood 2001;98(10):3074-81.
2001: Marilina Amabile; Barbara Giannini; Nicoletta Testoni; Vittorio Montefusco; Gianantonio Rosti; C Zardini; Carolina Terragna; Silvia Buonamici; Emanuela Ottaviani; Simona Soverini; Mauro Fiacchini; Simona Bassi; Antonio de Vivo; Elena Trabacchi; Giuseppe Saglio; Fabrizio Pane; Michele Baccarani; Sante Tura; giovanni martinelli
Real-time quantification of different types of bcr-abl transcript in chronic myeloid leukemia.
Haematologica 2001;86(3):252-9.
2000: Francesca Bonifazi; Antonio de Vivo; Gianantonio Rosti; Mario Tiribelli; Domenico Russo; Elena Trabacchi; Mauro Fiacchini; Enrico Montefusco; Michele Baccarani
Testing Sokal's and the new prognostic score for chronic myeloid leukaemia treated with alpha-interferon. Italian Cooperative Study Group on Chronic Myeloid Leukaemia.
British journal of haematology 2000;111(2):587-95.
2000: giovanni martinelli; Vittorio Montefusco; Marilina Amabile; Roberto M Lemoli; Carolina Terragna; Nicoletta Testoni; Emanuela Ottaviani; Gianantonio Rosti; Antonio de Vivo; Simonetta Rizzi; Domenico Russo; M Bregoli; Sante Tura
Quantitative evaluation of BCR-ABL amount of transcript post mobilization with G-CSF of peripheral blood stem cells from chronic myeloid leukemia patients in cytogenetic response.
Leukemia & lymphoma 2000;39(1-2):113-20.
2000: Giuseppe Visani; Gianantonio Rosti; Giuseppe Bandini; Patrizia Tosi; Alessandro Isidori; Michele Malagola; Marta Stanzani; giovanni martinelli; Pier Paolo Piccaluga; Nicoletta Testoni; Paolo Ricci; Sante Tura
Second chronic phase before transplantation is crucial for improving survival of blastic phase chronic myeloid leukaemia.
British journal of haematology 2000;109(4):722-8.
2000: giovanni martinelli; Vittorio Montefusco; Nicoletta Testoni; Marilina Amabile; Giuseppe Saglio; Emanuela Ottaviani; Carolina Terragna; Francesca Bonifazi; Gianantonio Rosti; Giuseppe Bandini; Sante Tura
Clinical value of quantitative long-term assessment of bcr-abl chimeric transcript in chronic myelogenous leukemia patients after allogeneic bone marrow transplantation.
Haematologica 2000;85(6):653-8.
2000: giovanni martinelli; Nicoletta Testoni; Marilina Amabile; Francesca Bonifazi; Antonio de Vivo; P Farabegoli; Carolina Terragna; Vittorio Montefusco; Emanuela Ottaviani; Giuseppe Saglio; Domenico Russo; Michele Baccarani; Gianantonio Rosti; Sante Tura
Quantification of BCR-ABL transcripts in CML patients in cytogenetic remission after interferon-alpha-based therapy.
Bone marrow transplantation 2000;25(7):729-36.
1999: D Russo; G Martinelli; Vittorio Montefusco; Marilina Amabile; Gianantonio Rosti; L Marin
Collection of Ph-negative progenitor cells from Ph+ CML patients in complete cytogenetic remission after long-term interferon-alpha therapy.
Haematologica 1999;84(10):953-5.
1999: Giovanna Meloni; Domenico Russo; Michele Baccarani; Nicoletta Testoni; giovanni martinelli; Renato Fanin; Elisa Zuffa; Gianantonio Rosti; Giuliana Alimena; Giuseppe Saglio; Franco Mandelli; Sante Tura
A prospective study of alpha-interferon and autologous bone marrow transplantation in chronic myeloid leukemia. The Italian Co-operative Study Group on Chronic Myeloid Leukemia.
Haematologica 1999;84(8):707-15.
1998: giovanni martinelli; Nicoletta Testoni; Vittorio Montefusco; Marilina Amabile; Giuseppe Saglio; Emanuela Ottaviani; Carolina Terragna; F Bonifazzi; Antonio de Vivo; Fabrizio Pane; Gianantonio Rosti; Sante Tura
Detection of bcr-abl transcript in chronic myelogenous leukemia patients by reverse-transcription-polymerase chain reaction and capillary electrophoresis.
Haematologica 1998;83(7):593-601.
1998: Michele Cavo; Giuseppe Bandini; Monica Benni; Alessandro Gozzetti; Sonia Ronconi; Gianantonio Rosti; Elena Zamagni; Roberto M Lemoli; Alessandro Bonini; A Belardinelli; Maria Rosa Motta; Simonetta Rizzi; Sante Tura
High-dose busulfan and cyclophosphamide are an effective conditioning regimen for allogeneic bone marrow transplantation in chemosensitive multiple myeloma.
Bone marrow transplantation 1998;22(1):27-32.
1998: Alessandro Bonini; Giuseppe Bandini; Gianantonio Rosti; Damiano Rondelli; Nicoletta Testoni; C Remiddi; Maria Rosa Motta; Simonetta Rizzi; S Mangianti; E Campanini; Elisa Zuffa; Sante Tura
Big BU/CY is associated with a favorable long-term outcome in patients allotransplanted for chronic myelogenous leukemia in chronic phase.
Bone marrow transplantation 1998;21(11):1085-9.
1998: Elisa Zuffa; Giuseppe Bandini; Alessandro Bonini; Maria Alessandra Santucci; giovanni martinelli; Gianantonio Rosti; Nicoletta Testoni; Alfonso Zaccaria; Sante Tura
Prior treatment with alpha-interferon does not adversely affect the outcome of allogeneic BMT in chronic phase chronic myeloid leukemia.
Haematologica 1998;83(3):231-6.
1998: Roberto M Lemoli; Giuseppe Bandini; Giuliana Leopardi; Gianantonio Rosti; Alessandro Bonini; A Fortuna; Damiano Rondelli; S Mangianti; Maria Rosa Motta; Simonetta Rizzi; Cristina Tassi; Michele Cavo; C Remiddi; Antonio Curti; Roberto Conte; Sante Tura
Allogeneic peripheral blood stem cell transplantation in patients with early-phase hematologic malignancy: a retrospective comparison of short-term outcome with bone marrow transplantation.
Haematologica 1998;83(1):48-55.
1996: Roberto M Lemoli; Gianantonio Rosti; Giuseppe Visani; Filippo Gherlinzoni; M C Miggiano; A Fortuna; Pier Luigi Zinzani; Sante Tura
Concomitant and sequential administration of recombinant human granulocyte colony-stimulating factor and recombinant human interleukin-3 to accelerate hematopoietic recovery after autologous bone marrow transplantation for malignant lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(11):3018-25.
1996: Francesco Lauria; Donatella Raspadori; MA Ventura; Damiano Rondelli; Pier Luigi Zinzani; Filippo Gherlinzoni; M C Miggiano; M Fiacchini; Gianantonio Rosti; Simonetta Rizzi; Sante Tura
Immunologic and clinical modifications following low-dose subcutaneous administration of rIL-2 in non-Hodgkin's lymphoma patients after autologous bone marrow transplantation.
Bone marrow transplantation 1996;18(1):79-85.
1996: M C Miggiano; Filippo Gherlinzoni; Gianantonio Rosti; Giuseppe Bandini; Giuseppe Visani; M Fiacchini; Paolo Ricci; Nicoletta Testoni; Maria Rosa Motta; Antonella Geromin; Simonetta Rizzi; A Belardinelli; S Mangianti; Silvia Manfroi; Sante Tura
Autologous bone marrow transplantation in late first complete remission improves outcome in acute myelogenous leukemia.
Leukemia 1996;10(3):402-9.
1996: giovanni martinelli; P Farabegoli; M Buzzi; G Panzica; Alfonso Zaccaria; Giuseppe Bandini; E Calori; Nicoletta Testoni; Gianantonio Rosti; Roberto Conte; C Remiddi; M Salvucci; Antonio de Vivo; Sante Tura
Fingerprinting of HLA class I genes for improved selection of unrelated bone marrow donors.
European journal of immunogenetics : official journal of the British Society for Histocompatibility and Immunogenetics 1996;23(1):55-65.
1996: Roberto M Lemoli; A Fortuna; Miriam Fogli; Gianantonio Rosti; Filippo Gherlinzoni; Giuseppe Visani; Lucia Catani; Alessandro Gozzetti; Sante Tura
Combined use of growth factors to stimulate the proliferation of hematopoietic progenitor cells after autologous bone marrow transplantation for lymphoma patients.
Acta haematologica 1996;95(3-4):164-70.
1995: Roberto M Lemoli; A Fortuna; Miriam Fogli; Filippo Gherlinzoni; Gianantonio Rosti; Lucia Catani; Alessandro Gozzetti; M C Miggiano; Sante Tura
Proliferative response of human marrow myeloid progenitor cells to in vivo treatment with granulocyte colony-stimulating factor alone and in combination with interleukin-3 after autologous bone marrow transplantation.
Experimental hematology 1995;23(14):1520-6.
1995: Alessandro Bonini; Giuseppe Bandini; T M Cirio; Patrizia Tosi; Gianantonio Rosti; Sante Tura
Methotrexate and delayed engraftment in allogeneic bone marrow transplantation.
Bone marrow transplantation 1995;16(5):729-30.
1995: Vilma Mantovani; giovanni martinelli; Michela Bragliani; M Buzzi; P Selva; E Collina; P Farabegoli; Gianantonio Rosti; Giuseppe Bandini; Sante Tura
Molecular analysis of HLA genes for the selection of unrelated bone marrow donor.
Bone marrow transplantation 1995;16(3):329-35.
1994: Patrizia Tosi; Giuseppe Bandini; Pier Luigi Tazzari; Donatella Raspadori; T M Cirio; Gianantonio Rosti; Alessandro Bonini; Roberto Conte; Sante Tura
Autoimmune neutropenia after unrelated bone marrow transplantation.
Bone marrow transplantation 1994;14(6):1003-4.
1994: B Gamberi; Giuseppe Bandini; Giuseppe Visani; Gianantonio Rosti; A Cenacchi; Maria Rosa Motta; F Fruet; E Calori; Simonetta Rizzi; Patrizia Tosi
Acute myeloid leukemia from diagnosis to bone marrow transplantation: experience from a single centre.
Bone marrow transplantation 1994;14(1):69-72.
1994: Giuseppe Bandini; A Belardinelli; Gianantonio Rosti; E Calori; Maria Rosa Motta; Simonetta Rizzi; C Benini; Sante Tura
Toxicity of high-dose busulphan and cyclophosphamide as conditioning therapy for allogeneic bone marrow transplantation in adults with haematological malignancies.
Bone marrow transplantation 1994;13(5):577-81.
1994: M C Miggiano; Filippo Gherlinzoni; Giuseppe Visani; A Belardinelli; Paolo Ricci; Gianantonio Rosti; Patrizio Mazza; Maria Rosa Motta; Simonetta Rizzi; Roberto M Lemoli
Hematological recovery after autologous bone marrow transplantation for high-grade non Hodgkin's lymphomas: a single center experience.
Haematologica 1994;79(3):225-32.
1994: Giuseppe Visani; Patrizia Tosi; Pier Luigi Zinzani; Silvia Manfroi; Alfonso Zaccaria; Nicoletta Testoni; Roberto M Lemoli; Gianantonio Rosti; S Pelliconi; Sante Tura
FLAG (fludarabine+cytosine arabinoside+G-CSF) induces complete remission in acute-phase chronic myeloid leukaemia: a case report.
British journal of haematology 1994;86(2):394-6.
1993: C Benini; Giuseppe Bandini; Maria Rosa Motta; A R Belardinelli; E Calori; Simonetta Rizzi; giovanni martinelli; Gianantonio Rosti; Elisabetta Trabetti; Pier Franco Pignatti
Donor origin of hematopoiesis after a case of allogeneic transplantation with cryopreserved marrow.
Haematologica 1993;78(6):414-5.
1993: Lucia Catani; Luigi Gugliotta; Monica Mattioli Belmonte; Nicola Vianelli; Filippo Gherlinzoni; M C Miggiano; A R Belardinelli; Gianantonio Rosti; E Calori; Giuseppe Bandini
Hypercoagulability in patients undergoing autologous or allogeneic BMT for hematological malignancies.
Bone marrow transplantation 1993;12(3):253-9.
1993: giovanni martinelli; Elisabetta Trabetti; Alfonso Zaccaria; P Farabegoli; M Buzzi; Nicoletta Testoni; E Calori; Giuseppe Bandini; Gianantonio Rosti; A Belardinelli
In vitro amplification of hypervariable DNA regions for the evaluation of chimerism after allogeneic BMT.
Bone marrow transplantation 1993;12(2):115-20.
1993: giovanni martinelli; M Buzzi; P Farabegoli; Nicoletta Testoni; Vilma Mantovani; E Calori; Gianantonio Rosti; Giuseppe Bandini; Michela Bragliani; G Panzica
New strategies for selection of unrelated bone marrow donors.
Bone marrow transplantation 1993;11 Suppl 1():31-2.
1992: Gianantonio Rosti; Giuseppe Bandini; A Belardinelli; E Calori; Sante Tura; Filippo Gherlinzoni; C Miggiano
Alteplase for hepatic veno-occlusive disease after bone-marrow transplantation.
Lancet 1992;339(8807):1481-2.
1991: Giuseppe Bandini; Elisa Zuffa; Gianantonio Rosti; R Battista; E D'Emilio; Franco Leoni; Stefania Ciolli; T Barbui; R Bassan; Giuseppe Todeschini
Long-term outcome of adults with acute myelogenous leukaemia: results of a prospective, randomized study of chemotherapy with a minimal follow-up of 7 years.
British journal of haematology 1991;77(4):486-90.
1991: Alfonso Zaccaria; Gianantonio Rosti; Nicoletta Testoni; Maria Alessandra Santucci; A Tassinari; B Celso; M Buzzi; M C Miggiano; Sante Tura
Cytogenetic events after bone marrow transplantation for Philadelphia chromosome positive chronic myeloid leukemia.
Leukemia research 1991;15(5):289-96.
1991: Michele Cavo; Sante Tura; Gianantonio Rosti; M Grimaldi; Giuseppe Bandini; M A Bonelli; E Calori; Simonetta Rizzi; M T Van Lint; A Bacigalupo
Allogenic BMT for multiple myeloma (MM). The Italian experience.
Bone marrow transplantation 1991;7 Suppl 2():31.
1991: Gianantonio Rosti; Alfonso Zaccaria; Nicoletta Testoni; B Celso; C Miggiano; Sante Tura; M Sessarego; A M Marmont; F Gualandi; F Francesco
Cytogenetic follow-up after allogeneic bone marrow transplantation for Ph+ CML: update of the European Cooperative Study.
Bone marrow transplantation 1991;7 Suppl 2():19.
1990: Gianantonio Rosti; Giuseppe Bandini; M C Miggiano; L Albertazzi; Paolo Ricci; F Verlicchi; S Pileri; Sante Tura
An unusual case of Candida tropicalis sepsis in a patient submitted to allogeneic bone marrow transplantation.
Haematologica 1990;75(5):480-1.
1990: F Verlicchi; Paolo Ricci; A Bassi; D Benfenati; Giuseppe Bandini; Gianantonio Rosti; E Calori; C Borghi; Sante Tura
Systemic broad-spectrum antimicrobial prophylaxis in hematological patients after intensive antineoplastic chemotherapy.
Haematologica 1990;75(1):91-3.
1989: Gianantonio Rosti; Alfonso Zaccaria; Nicoletta Testoni; B Celso; Giuseppe Bandini; A Tassinari; L Albertazzi; C Miggiano; Sante Tura; M Sessarego
Cytogenetic monitoring in CML patients treated with BMT.
Bone marrow transplantation 1989;4 Suppl 4():95-7.
1989: Sante Tura; Michele Cavo; Gianantonio Rosti; Giuseppe Bandini; marco gobbi; M Grimaldi; M C Miggiano; L Albertazzi; M A Bonelli
Allogeneic bone marrow transplantation for multiple myeloma.
Bone marrow transplantation 1989;4 Suppl 4():106-8.
1989: Giuseppe Bandini; Gianantonio Rosti; Michele Cavo; L Albertazzi; Sante Tura
Acceleration of autologous hematopoietic recovery by GM-CSF after allograft rejection.
Haematologica 1989;74(6):627-8.
1989: Nicoletta Testoni; Alfonso Zaccaria; B Celso; A Tassinari; Gianantonio Rosti; Sante Tura
5q- and t(2;11) in a patient with M2 acute non-lymphocytic leukemia. Case report.
Haematologica 1989;74(6):595-9.
1989: Alfonso Zaccaria; Nicoletta Testoni; A Tassinari; B Celso; Feyruz V Rassool; Giuseppe Saglio; Angelo Guerrasio; Gianantonio Rosti; Sante Tura
Cytogenetic and molecular studies in patients with chronic myeloid leukemia and variant Philadelphia translocations.
Cancer genetics and cytogenetics 1989;42(2):191-201.
1989: Giuseppe Bandini; Gianantonio Rosti; Michele Cavo; L Albertazzi; Simonetta Rizzi; Maria Rosa Motta; marco gobbi; Cristina Tassi; Pier Luigi Tazzari; C Miggiano
[Allogeneic bone marrow transplantation in multiple myeloma].
Haematologica 1989;74(5 Suppl):463-72.
1989: Giuseppe Visani; M C Re; R Colombini; A Cenacchi; G Furlini; G Sermasi; Patrizia Tosi; Gianantonio Rosti; Domenico Russo; Elisa Zuffa
Human immunodeficiency virus testing in acute leukemia patients transfused between 1978 and 1985: a retrospective study on 91 cases.
Haematologica 1989;74(4):371-3.
1988: Alfonso Zaccaria; Gianantonio Rosti; M Sessarego; F Frassoni; A Marmont; M Galimberti; Donatella Baronciani; A Filippetti; Paolo Di Bartolomeo; Gabriele Di Girolamo
Relapse after allogeneic bone marrow transplantation for Philadelphia chromosome positive chronic myeloid leukemia: cytogenetic analysis of 24 patients.
Bone marrow transplantation 1988;3(5):413-23.
1988: Alfonso Zaccaria; A Tassinari; Giuseppe Saglio; Angelo Guerrasio; Nicoletta Testoni; B Celso; Gianantonio Rosti; Sante Tura
Cytogenetic and molecular analyses in Philadelphia chromosome positive acute lymphoblastic leukaemia.
British journal of haematology 1988;69(3):424-6.
1988: A Tassinari; Alfonso Zaccaria; Giuseppe Saglio; Angelo Guerrasio; Nicoletta Testoni; B Celso; Gianantonio Rosti; G R Cambrin; Sante Tura
Molecular biology studies in Philadelphia chromosome-negative chronic myeloid leukemia.
Haematologica 1988;73(4):326-7.
1988: Giuseppe Visani; Annalisa Patrizi; P Ricci; R Colombini; A Balducci; Patrizia Tosi; Alfonso Zaccaria; Gianantonio Rosti; Claudio Varotti
Sweet's syndrome: association with accelerated phase of chronic myeloid leukemia.
Acta haematologica 1988;79(4):207-10.
1987: Alfonso Zaccaria; Gianantonio Rosti; N Testoni; G Alimena; W Arcese; G Bandini; M Boogaerts; F Carbonell; A Ferrant; A Filippetti
Chromosome studies in patients with Philadelphia chromosome-positive chronic myeloid leukemia submitted to bone marrow transplantation--results of a European Cooperative Study.
Cancer genetics and cytogenetics 1987;26(1):5-13.
1987: Gianantonio Rosti; Alfonso Zaccaria; Nicoletta Testoni; B Celso; P Ricci; Giuseppe Bandini; Michele Baccarani; Sante Tura
Chromosome patterns of relapses following allogeneic bone marrow transplantation for acute non-lymphocytic leukemia. Description of three cases.
Haematologica 1987;72(2):111-4.
1987: G Bandini; E Strocchi; P Ricci; Simonetta Rizzi; S Boschi; C Guardigli; E Calori; Maria Rosa Motta; V Giudice; Gianantonio Rosti
Ciclosporin A: correlation of blood levels with acute graft-versus-host disease after bone marrow transplantation.
Acta haematologica 1987;78(1):6-12.